Navigation Links
Amgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
Date:1/25/2013

THOUSAND OAKS, Calif., Jan. 25, 2013 /PRNewswire/ -- In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen (NASDAQ: AMGN) today stated that it supports state biosimilars initiatives that focus on sound science and patient safety. As a biotech company developing both innovator biologics and biosimilars, Amgen believes that patient safety does not stop at drug approval. 

"Amgen endorses state policies that would put patients first and, in doing so, increase confidence in the biosimilar pathway. It is important to have consistent policies in place at the federal and state level," said Scott Foraker , vice president and general manager of biosimilars at Amgen. 

States' efforts to create safe substitution rules for interchangeable biologics will help accelerate the successful implementation of the U.S. biosimilars pathway. Regulatory authorities in Europe and the U.S. have emphasized the need for long-term safety monitoring of biologics. Biologic medicines are different than traditional chemical drugs in several important ways. Biologics are so complex that they can usually only be made by a living cell.  In fact, when made by different manufacturers, they differ from each other.  They are also very large compared to chemical drugs and can be more sensitive to storage and handling. As a result biologic medicines have the potential to cause an unwanted immune response, which can show up months after taking the medicine. This emphasizes why Amgen believes state pharmacy acts must enhance safety monitoring of substituted biologics.

Amgen is helping educate state policymakers on these considerations to ensure that physicians, patients and pharmacists share important in
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgens Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
2. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
3. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
4. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
5. Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
6. Amgen Supports Assistance for Patients Affected by Hurricane Sandy
7. Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
8. Amgen To Present At The Morgan Stanley Global Healthcare Conference
9. Amgen To Present At The Baird Healthcare Conference
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Grade Sodium Chloride Market by Applications, ... report to their offering. The pharmaceutical ... CAGR of 6.9% between 2014 and 2019 in terms ... 690 KT by 2019. The report on ...
(Date:7/6/2015)... -- Celtaxsys, Inc., a clinical stage pharmaceutical development company ... orphan inflammatory disease indications, announced today that it has ... (FDA) to begin a Phase 2 clinical trial of ... patients in the US. The regulatory submissions to the ... be filed soon after. This groundbreaking clinical study, testing ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled ... by the time they turn age 35 a quarter of all women in the U.S. will ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, who ...
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to Cover: ... there is a large gap between the unmet health priorities in the region ... outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone conference, ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud ... Post Graduate Teaching Award on behalf of the department of Family Practice. , “This ... field to be practicing in. The technology is changing so rapidly and we are ...
(Date:7/6/2015)... ... July 06, 2015 , ... Longevity, the highest regarded provider ... Walk-In Urgent Care to offer on-site health screenings. These ultrasound screenings detect early ... affordable and accurate and run about an hour long with same day results. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects ... medical field to access and use this “Big Data” to improve health and cut ... Executive Officer of the Mount Sinai Health System in New York City. Physicians will ...
Breaking Medicine News(10 mins):Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5
... Life Sciences has submitted an application with the Drug ... phase-1 clinical trials of its new drug Suvn-502 for ... ,'Treatment for Alzheimer's disease and Schizophrenia is ... to discover drugs that address significant unmet medical needs,' ...
... Nepalese doctors has developed a drug that is more ... reported Friday . ,The drug also costs ... Organization (WHO), reported The Himalayan Times daily.Doctors at the ... typhoid patients. ,,The team compared the effectiveness ...
... 1,763 food shipments from India, 1,480 from Mexico and 1,368 ... year . ,Some of India's spices, seeds and ... found too filthy to eat. Chinese products like seafood, bean ... has reported. ,,But the FDA did not reveal the ...
... for the high-tech dental lasers used mainly to prepare cavities ... conducted by researchers in Austria, these advanced dental lasers can ... study credits the progress of miniaturized, flexible fiber tips for ... treatment. ,Dr. Ulrich Schoop and a team of ...
... on the Yamuna River that flows past India's capital, it's easy ... surface by rotting sewage -- and that's after at least ... ,Now, with New Delhi to host the Commonwealth Games in ... built on the stinking river's banks, India must do in three ...
... the end of the last century death rates from breast ... Long waiting lists, resulting in delayed diagnosis and treatment, were ... is failing breast cancer patients and needs to be reviewed ... brought in the 2 week wait rule which stipulated that ...
Cached Medicine News:Health News:US Rejects More Food from India Than from Any Other Country 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 3Health News:Two Week Wait Rule Not Working With Breast Cancer Patients 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: